Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Prediction Value of XRCC 1 Gene Polymorphism on the Survival of Ovarian Cancer Treated by Adjuvant Chemotherapy

  • Miao, Jin (Department of Gynecology and Obstetrics, the First Affiliated Hospital of Jinan University) ;
  • Zhang, Xian (Department of Gynecology and Obstetrics, the First Affiliated Hospital of Jinan University) ;
  • Tang, Qiong-Lan (Department of Pathology, the Sun Yat-sen Memorial Hospital of Sun Yat-sen University) ;
  • Wang, Xiao-Yu (Department of Gynecology and Obstetrics, the First Affiliated Hospital of Jinan University) ;
  • Kai, Li (Department of Oncology, Chinese Medical Sciences University)
  • Published : 2012.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: We conducted a prospective study to test the association between three amino acid substitution polymorphismic variants of DNA repair genes, XRCC1 (Arg194Trp), XRCC1(Arg280His) and XRCC1 (Arg399Gln), and clinical outcome of ovarian cancer patients undergoing adjuvant chemotherapy. Methods: 195 patients with primary advanced ovarian cancer and treated by adjuvant chemotherapy were included in our study. All were followed-up from Jan. 2007 to Jan. 2012. Genotyping of XRCC1 polymorphisms was conducted by TaqMan Gene Expression assays. Results: The XRCC1 194 Trp/Trp genotype conferred a significant risk of death from ovarian cancer when compared with Arg/Arg (HR=1.56, 95%CI=1.04-3.15). Similarly, those carrying the XRCC1 399 Gln/Gln genotype had a increased risk of death as compared to the XRCC1 399Arg/Arg genotype with an HR (95% CI) of 1.98 (1.09-3.93). Conclusion: This study is the first to provide evidence that XRCC1 gene polymorphisms would well be useful as surrogate markers of clinical outcome in ovarian cancer cases undergoing adjuvant chemotherapy.

Keywords

References

  1. Allan JM, Smith AG, Wheatley K, et al (2004). Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood, 104, 3872-7. https://doi.org/10.1182/blood-2004-06-2161
  2. Brem R, Hall J (2005). XRCC1 is required for DNA single-strand break repair in human cells. Nucleic Acids Res, 33, 2512-20. https://doi.org/10.1093/nar/gki543
  3. Britten RA, Liu D, Tessier A, et al (2000). ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer, 89, 453-7. https://doi.org/10.1002/1097-0215(20000920)89:5<453::AID-IJC9>3.0.CO;2-E
  4. Chang-Claude J, Popanda O, et al (2005). Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res, 11, 4802-9. https://doi.org/10.1158/1078-0432.CCR-04-2657
  5. Cui Z, Yin Z, Li X, et al (2012). Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis. BMC Cancer, 12, 71. https://doi.org/10.1186/1471-2407-12-71
  6. Harries M, Kaye SB (2001). Recent advances in the treatment of epithelial ovarian cancer. Expert Opin Investig Drugs, 10, 1715-24. https://doi.org/10.1517/13543784.10.9.1715
  7. Hirata H, Hinoda Y, Tanaka Y, et al (2007). Polymorphisms of DNA repair genes are risk factors for prostate cancer. Eur J Cancer, 43, 23107.
  8. Hogberg T, Glimelius B, Nygren P, et al (2001). A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol, 40, 340-60. https://doi.org/10.1080/02841860151116420
  9. Huang WY, Chow WH, Rothman N, et al (2005). Selected DNA repair polymorphisms and gastric cancer in Poland. Carcinogenesis, 26, 1354-9. https://doi.org/10.1093/carcin/bgi084
  10. Jakubowska A, Gronwald J, Menkiszak J, et al (2010). BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Res Treat, 119, 201-11. https://doi.org/10.1007/s10549-009-0390-5
  11. Khrunin AV, Moisseev A, Gorbunova V, et al (2010). Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J, 10, 54-61. https://doi.org/10.1038/tpj.2009.45
  12. Kim HS, Kim MK, Chung HH, et al (2009). Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol, 113, 264-9. https://doi.org/10.1016/j.ygyno.2009.01.002
  13. Kiyohara C, Takayama K, Nakanishi Y (2006). Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer, 54, 267-83. https://doi.org/10.1016/j.lungcan.2006.08.009
  14. Krivak TC, Darcy KM, Tian C, et al (2011). Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol, 122, 121-6. https://doi.org/10.1016/j.ygyno.2011.03.027
  15. La Torre F, Orlando A, Silipigni A, et al (1997). Increase of oxygen free radicals and their derivatives in chemoand radiation treated neoplasm patients. Minerva Med, 88, 121-6.
  16. Liang J, Jiang T, Yao RY, et al (2010). The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol, 66, 493-500. https://doi.org/10.1007/s00280-009-1186-3
  17. Liao WY, Shih JY, Chang GC, et al (2012). Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in nonsmall-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol, 7, 973-81. https://doi.org/10.1097/JTO.0b013e31824fe98c
  18. Liu YP, Ling Y, Zhang YP, et al (2011). Predictive values of platinum-rel`1ated gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy. Zhonghua Yi Xue Za Zhi, 91, 256-9.
  19. Nazarkina ZK, Khodyreva SN, Marsin S, et al (2007). XRCC1 interactions with base excision repair DNA intermediates. DNA Repair (Amst), 6, 254-64. https://doi.org/10.1016/j.dnarep.2006.10.002
  20. Piccart MJ, Lamb H, Vermorken JB, et al (2001). Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol, 12, 1195-203. https://doi.org/10.1023/A:1012259625746
  21. Price N (2004). Impact of genetic polymorphisms in DNA repair enzymes on drug resistance in lung cancer. Clin Lung Cancer, 6, 79-82. https://doi.org/10.1016/S1525-7304(11)70205-4
  22. Ren S, Zhou S, Zhang L, et al (2010). High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Invest, 28, 1078-83. https://doi.org/10.3109/07357901003735659
  23. Savas S, Kim DY, Ahmad MF, et al (2004). Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev, 13, 801-7.
  24. Shirota Y, Stoehlmacher J, Brabender J, et al (2001). ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol, 19, 4298-304.
  25. Siddiqui-Jain A, Bliesath J, Macalino D, et al (2012). CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy. Mol Cancer Ther, 11, 994-1005. https://doi.org/10.1158/1535-7163.MCT-11-0613
  26. Simon GR, Sharma S, Cantor A, et al (2005). ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest, 127, 978-83. https://doi.org/10.1378/chest.127.3.978
  27. Stern MC, Siegmund KD, Conti DV, et al (2006). XRCC1, XRCC3, and XPD polymorphisms as modifiers of the effect of smoking and alcohol on colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev, 15, 2384-90. https://doi.org/10.1158/1055-9965.EPI-06-0381
  28. Weijl NI, Cleton FJ, Osanto S, et al (1997). Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev, 23, 209-40. https://doi.org/10.1016/S0305-7372(97)90012-8
  29. Williams SD, Blessing JA, Moore DH, et al (1989). Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group. Ann Intern Med, 111, 22-7. https://doi.org/10.7326/0003-4819-111-1-22
  30. Zhou W, Gurubhagavatula S, Liu G, et al (2004). Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced nonsmall cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res, 10, 4939-43. https://doi.org/10.1158/1078-0432.CCR-04-0247

Cited by

  1. Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy? vol.5, pp.1664-8021, 2014, https://doi.org/10.3389/fgene.2014.00391
  2. Understanding the role of epigenomic, genomic and genetic alterations in the development of endometriosis (Review) vol.9, pp.5, 2014, https://doi.org/10.3892/mmr.2014.2057
  3. Identification of XRCC1 Arg399Gln and XRCC3 Thr241Met Polymorphisms in a Turkish Population and Their Association with the Risk of Chronic Lymphocytic Leukemia vol.31, pp.3, 2015, https://doi.org/10.1007/s12288-014-0482-1
  4. Single nucleotide polymorphisms (SNPs) of hOGG1 and XRCC1 DNA repair genes and the risk of ovarian cancer in Polish women vol.36, pp.12, 2015, https://doi.org/10.1007/s13277-015-3707-5
  5. Lack of Association between an XRCC1 Gene Polymorphism and Colorectal Cancer Survival in Thailand vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.2055
  6. XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy vol.97, pp.45, 2018, https://doi.org/10.1097/MD.0000000000012996
  7. DNA damage repair in ovarian cancer: unlocking the heterogeneity vol.11, pp.1, 2018, https://doi.org/10.1186/s13048-018-0424-x